-+ 0.00%
-+ 0.00%
-+ 0.00%

On the afternoon of November 18, the Jiangsu Provincial Government held a special promotion conference on the high-quality development of the “6+6” industry. At the conference, China Pharmaceutical University had an exchange on behalf of the Jiangsu Biomedical Industry Alliance. Experts from Huatai Securities gave presentations on industry development trends. Companies such as Hengrui Pharmaceutical, Ruizheng Gene, Mibotech, Digi Pharmaceuticals, Kingsley Biotech, and Sandieji spoke successively. The conference carefully examined the development situation of the biomedical and brain-computer interface industries in the province, and called for stepping up the detailed implementation of the three-year action plan to promote the high-quality development of the biomedical industry in Jiangsu, strengthening basic research and applied research on common technologies, promoting research on key core technologies, and implementing a number of “shortcoming repair” research projects. Clear admission channels for innovative pharmaceutical devices, actively explore “Medical+Commercial Insurance” multiple payment models to help the clinical application of innovative products; create a new “AI+ biomedicine” paradigm, vigorously cultivate innovators, lay out and build high-quality data sets and large R&D industry application models; support corporate equity financing, cross-border cooperation, mergers and acquisitions, and standardize supply and demand matchmaking activities to promote the deep integration of the industrial chain, capital chain, talent chain and innovation chain.

Zhitongcaijing·11/20/2026 04:09:05
Listen to the news
On the afternoon of November 18, the Jiangsu Provincial Government held a special promotion conference on the high-quality development of the “6+6” industry. At the conference, China Pharmaceutical University had an exchange on behalf of the Jiangsu Biomedical Industry Alliance. Experts from Huatai Securities gave presentations on industry development trends. Companies such as Hengrui Pharmaceutical, Ruizheng Gene, Mibotech, Digi Pharmaceuticals, Kingsley Biotech, and Sandieji spoke successively. The conference carefully examined the development situation of the biomedical and brain-computer interface industries in the province, and called for stepping up the detailed implementation of the three-year action plan to promote the high-quality development of the biomedical industry in Jiangsu, strengthening basic research and applied research on common technologies, promoting research on key core technologies, and implementing a number of “shortcoming repair” research projects. Clear admission channels for innovative pharmaceutical devices, actively explore “Medical+Commercial Insurance” multiple payment models to help the clinical application of innovative products; create a new “AI+ biomedicine” paradigm, vigorously cultivate innovators, lay out and build high-quality data sets and large R&D industry application models; support corporate equity financing, cross-border cooperation, mergers and acquisitions, and standardize supply and demand matchmaking activities to promote the deep integration of the industrial chain, capital chain, talent chain and innovation chain.